A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Life expectancy \> 3 months.
• One of the following histologically or cytologically confirmed advanced solid tumors: head and neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), breast carcinoma (hormone receptor-positive \[HR+\] and Human Epidermal Growth Receptor 2 negative \[HER2-\] that has progressed to a prior treatment with Cluster of Differentiation 4 \[CD4\] / Cyclin-Dependent Kinase 6 \[CDK6\] inhibitor), or platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers (HGSOC).
• Must have disease that is advanced (ie, surgery or radiotherapy are not considered to be potentially curative), recurrent, or metastatic following SoC treatments.
• Adequate hematological, liver, and renal function.
• Must have tumor lesion(s) or metastases amenable to biopsy, excluding bone metastases.
Locations
United States
Michigan
START Midwest
RECRUITING
Grand Rapids
Texas
START San Antonio
RECRUITING
San Antonio
Utah
START Mountain Region
RECRUITING
West Valley City
Other Locations
Belgium
GZA Ziekenhuizen - Campus Sint-Augustinus
RECRUITING
Antwerp
Clinique Universitaires Saint-Luc
RECRUITING
Brussels
Institute Jules Bordet
RECRUITING
Brussels
CHU Sart Tilman
RECRUITING
Liège
United Kingdom
The Beatson West of Scotland Cancer Centre
RECRUITING
Glasgow
UCL Hospitals NHS Foundation Trust
RECRUITING
London
The Christie NHS Foundation Trust
RECRUITING
Manchester
Newcastle Upon Tyne NHS Foundation Trust
RECRUITING
Newcastle Upon Tyne
Oxford University Hospitals NHS Foundation Trust
RECRUITING
Oxford
Contact Information
Primary
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.